symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NKTX,3.14,0.043428,406389,154042748,0,1.28-13.815,1.66,"Nkarta, Inc.",USD,0001787400,US65487U1088,65487U108,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.nkartatx.com,"Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.",Mr. Paul J. Hastings,Healthcare,US,169,415 582 4923,6000 Shoreline Court,South San Francisco,CA,94080,,0,https://financialmodelingprep.com/image-stock/NKTX.png,2020-07-10,False,False,True,False,False
